Bracco Diagnostics Inc.推出了 HeartSee™的更新版本，新增了功能并扩展了对用于冠状动脉疾病诊断的尖端技术的访问-动脉网

Bracco Diagnostics Inc. Launches Update to HeartSee™ With New Features and Expanded Access to Cutting-edge Technology for Coronary Artery Disease Diagnosis

CISION 等信源发布 2025-03-17 19:59



可切换为仅中文







Bracco Diagnostics Inc. (PRNewsFoto/Bracco Diagnostics Inc.) (PRNewsfoto/Bracco Group)

布拉科诊断公司 (PRNewsFoto/布拉科诊断公司) (PRNewsfoto/布拉科集团)

HeartSee Logo

心视标志

PRINCETON, N.J.

普林斯顿，新泽西州

，

March 17, 2025

2025年3月17日

/PRNewswire/ -- Bracco Diagnostics Inc., a U.S. subsidiary of Bracco Imaging S.p.A, one of the world's leading companies in the diagnostic imaging business, announced today significant upgrades to its innovative HeartSee

/PRNewswire/ -- Bracco Diagnostics Inc.是Bracco Imaging S.p.A的美国子公司，也是全球诊断成像业务的领先公司之一，今天宣布对其创新的HeartSee进行了重大升级。

™

software, a leading diagnostic tool used in myocardial blood flow (MBF) quantification with cardiac positron emission tomography (PET) imaging. These updates, which will be rolled out universally to existing users through the launch of v4.0, are designed to enhance usability, broaden access, and increase data security.

软件，这是一种领先的心肌血流（MBF）定量诊断工具，用于心脏正电子发射断层扫描（PET）成像。这些更新将通过推出4.0版本普遍推送给现有用户，旨在提高可用性、扩大访问范围并增强数据安全性。

The new features will further support physicians in the diagnosis and treatment of coronary artery disease (CAD)..

新功能将进一步支持医生对冠心病（CAD）的诊断和治疗。

'Bracco Diagnostics has been at the forefront of cardiac PET imaging for over three decades. The latest updates to our HeartSee software represent a significant milestone for our company, as they not only enhance the usability of this diagnostic tool but also broaden access to critical heart health insights,' said .

“Bracco Diagnostics 在心脏 PET 成像领域一直处于前沿地位已超过三十年。我们 HeartSee 软件的最新更新对公司而言是一个重要的里程碑，因为它们不仅提升了这一诊断工具的可用性，还拓宽了获取心脏健康关键信息的途径，”该公司表示。

Derek Steptoe

德里克·斯蒂普

, Senior Manager of Nuclear Cardiology, Bracco. 'These improvements underscore our dedication to supporting physicians in making informed decisions that improve patient outcomes. We believe the new features of HeartSee will set a new standard in cardiac care, helping to detect and treat coronary artery disease more effectively and efficiently than ever before.'.

，核心脏病学高级经理，布拉科。“这些改进强调了我们致力于支持医生做出改善患者预后的明智决策。我们相信 HeartSee 的新功能将树立心脏护理的新标准，帮助比以往更有效率和高效地检测和治疗冠状动脉疾病。”

The updates to HeartSee include:

HeartSee 的更新包括：

New Diagnostic Features:

新诊断功能：

HeartSee is the only MBF software with the ability to measure subendocardial ischemia, which can provide additional information when other imaging results cannot explain a patient's symptoms. Also included is a new feature called relative stress flow that provides an indirect assessment of subendocardial border zones in areas with mildly reduced Coronary Flow Capacity (CFC), excluding areas of scar.

HeartSee 是唯一一款能够测量心内膜下缺血的 MBF 软件，在其他影像学结果无法解释患者症状时，可提供更多信息。新增的一项功能名为相对应力流，该功能可对冠状动脉流量能力 (CFC) 轻度降低区域的心内膜下边界区进行间接评估，排除瘢痕区域。

The addition of ejection fraction data makes HeartSee a comprehensive diagnostic solution in a single package..

添加射血分数数据使 HeartSee 成为一个全面的单一诊断解决方案。

Broad Access

广泛的访问权限

: With dedicated field support, comprehensive physician training, and compatibility with the Windows 10/11 operating system, HeartSee offers seamless integration into hospitals and clinics, making it easy for a wide range of clinicians and patients to benefit from this advanced diagnostic tool.

通过专门的现场支持、全面的医生培训以及与 Windows 10/11 操作系统的兼容性，HeartSee 能够无缝集成到医院和诊所中，使广泛的临床医生和患者能够轻松受益于这一先进的诊断工具。

'Since HeartSee was introduced in 2018, it has been instrumental in helping physicians accurately identify the right patients for intervention, thereby improving treatment outcomes and reducing the need for invasive procedures like stents or surgery,' said

“自从 HeartSee 于 2018 年推出以来，它在帮助医生准确识别适合进行干预的患者方面发挥了重要作用，从而改善了治疗效果，并减少了对支架或手术等侵入性手术的需求，”

Sergey Kachur

谢尔盖·卡丘尔

, MD, FACC, and Director of Echocardiography and Nuclear Cardiology at Ascension Sacred Heart. 'Our cardiac PET program was built with the express intention of implementing HeartSee because of its unique capabilities.'

医学博士，FACC，阿森松圣心医院超声心动图和核心脏病学主任。“我们的心脏PET项目建立的初衷是为了实施HeartSee，因为其具备独特的能力。”

MBF and CFR data have become increasingly crucial and recognized for managing CAD. In addition to measuring absolute MBF and CFR, HeartSee offers the added benefit of assessing regional defects in the heart and calculating CFC. For years, HeartSee has helped physicians accurately identify the right patients for the right procedures to help treat and prevent this all-too-common heart disease..

MBF和CFR数据在冠心病的管理中变得越来越重要且受到认可。除了测量绝对MBF和CFR之外，HeartSee还提供了评估心脏区域性缺陷和计算CFC的额外优势。多年来，HeartSee帮助医生准确识别适合特定手术的患者，以帮助治疗和预防这种十分常见的心脏病。

1,2

As Dr.

如博士所述。

James Feldman

詹姆斯·费尔德曼

of Memorial Katy Cardiology Associates in

纪念凯蒂心脏病学协会的

Cypress, Texas

德克萨斯州赛普雷斯

, says, 'As time has passed, we really can't see ourselves reading studies without HeartSee. We get so much extra data. It's helpful for all of us.'

，说道：“随着时间的推移，我们真的无法想象没有HeartSee的情况下阅读研究。我们获得了如此多的额外数据。这对我们所有人都很有帮助。”

Please see Important Safety Information below.

请参阅以下重要的安全信息。

INDICATIONS FOR USE

使用指征

HeartSee

心视

™

Software for cardiac positron emission tomography (PET) is indicated for determining regional and global absolute rest and stress myocardial perfusion in cc/min/g, Coronary Flow Reserve and their combination into the Coronary Flow Capacity (CFC) Map in patients with suspected or known coronary artery disease (CAD) in order to assist clinical interpretation of PET perfusion images by quantification of their severity..

用于心脏正电子发射断层扫描 (PET) 的软件适用于确定疑似或已知冠状动脉疾病 (CAD) 患者的局部和整体绝对静息及应激心肌血流量（cc/min/g）、冠状动脉血流储备及其组合成的冠状动脉流量能力 (CFC) 图，以便通过量化其严重程度来协助 PET 灌注图像的临床解读。

HeartSee

心视

™

is intended for use by trained professionals such as nuclear technicians, nuclear medicine or nuclear cardiology physicians, or cardiologists with appropriate training and certification. The clinician remains ultimately responsible for the final assessment and diagnosis based on standard practices, clinical judgment and interpretation of PET images or quantitative data..

旨在供训练有素的专业人员使用，例如核技术员、核医学或核心脏病学医生，或经过适当培训和认证的心脏病专家。临床医生最终负责根据标准实践、临床判断以及对PET图像或定量数据的解读来进行最终评估和诊断。

HEARTSEE is a trademark of The

HEARTSEE 是 The 的商标

University of Texas Health Science Center at Houston

德克萨斯大学休斯顿健康科学中心

on behalf of the Board of Regents of The

代表董事会

University of Texas

德克萨斯大学

System, and used under a license by Bracco Diagnostics Inc.

系统，并由Bracco Diagnostics Inc.授权使用。

Microsoft and Windows are registered trademarks of Microsoft Corporation.

微软和Windows是微软公司的注册商标。

For additional information about Bracco's products, and for full prescribing information, please visit

有关 Bracco 产品的更多信息以及完整的处方信息，请访问

http://imaging.bracco.com/us-en

。

Bracco Diagnostics Inc. Media Relations (

布拉科诊断公司媒体关系 (

USA

美国

Kimberly Gerweck

金伯利·格威克

Senior Compliance & Communications Manager

高级合规与传播经理

BDIMediaContact@diag.bracco.com

T: +1 609.524.2777

电话：+1 609.524.2777

关注我们

bracco.com

领英

YouTube

Bracco is an

布拉科是

international Group

国际集团

active in over 100 countries worldwide in the healthcare sector and a leader in

在全球100多个国家的医疗保健领域活跃，并且是领导者

diagnostic imaging

诊断成像

. It has 3,700 employees and annual total consolidated revenues of around

。公司拥有3700名员工，年总收入约为

1.8 billion euros

18亿欧元

, 88% of which are from international sales. In the

，其中88%来自国际销售。在

Research and Development

研究与开发

area, the company invests approximately 10% of reference turnover in the imaging diagnostics and medical devices sectors and has a portfolio comprising over 2,600 patents.

在成像诊断和医疗器械领域，该公司投资了大约10%的参考营业额，并拥有包含2600多项专利的投资组合。

Gould KL, Johnson NP, Roby A, et al. Regional Artery Specific Thresholds of Quantitative Myocardial Perfusion by PET Associated With Reduced Myocardial Infarction and Death After Revascularization in Stable Coronary Artery Disease. J Nucl Med 2019; 60:410–417. DOI: 10.2967/jnumed.118.211953.

Gould KL, Johnson NP, Roby A, 等。PET定量心肌灌注的区域动脉特异性阈值与稳定型冠状动脉疾病血运重建后心肌梗死和死亡减少相关。《核医学杂志》2019; 60:410–417。DOI: 10.2967/jnumed.118.211953。

Gould KL, Johnson NP, Roby A, et. al. Coronary flow capacity and survival prediction after revascularization: physiological basis and clinical implications.

Gould KL, Johnson NP, Roby A, 等。冠状动脉血流储备与血运重建后的生存预测：生理学基础与临床意义。

Eur Heart J

欧洲心脏杂志

. 2024; 45, 181-194. DOI: 0.1093/eurheartj/ehad812.

SOURCE Bracco Group

来源：博莱科集团

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+